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ABSTRACT 
The mechanical properties of the structural tissues of the eye (cornea, sclera, and vitreous) 
are critical for vision. Age and disease can cause changes in their physical properties and 
compromise visual acuity; in the extreme, such changes can lead to blindness. Thus, there 
is great interest in understanding the mechanical properties of ocular tissues and in 
developing appropriate therapeutic strategies. 
The goal of this thesis is to discover and manipulate the molecular mechanisms that 
determine the bulk physical properties of the vitreous and the cornea. These tissues are both 
ordered biocomposites of fibrous collagen embedded in soft matrices of proteoglycans 
(PGs) and glycosaminoglycans (GAGs). The hydration state, mole fraction, and 
particularly the organization of these components determine the mechanical properties of 
the respective tissues. Whereas the mechanical strength of these tissues has traditionally 
been attributed to their collagenous components, we present evidence that the PGs and 
GAGs also make significant contributions. We also suggest hypotheses regarding the 
mechanisms by which the carbohydrate components contribute and how they can be 
utilized for therapeutic purposes.  
In order to study the unique physical properties of the vitreous, novel instrumentation was 
developed. We describe the use of cleated surfaces on parallel disk tools to quantitatively 
measure the rheological properties of diverse slip-prone fluids and soft materials. Densely-
packed protrusions (0.45mm x 0.45mm cross section x 0.6mm length, 0.9mm apart) 
penetrate the slip layer, preventing significant flow between cleats. This creates a no-slip 
boundary ~ 0.16mm below their tips, which serves as the sample gap boundary, in direct 
analogy to the parallel plate geometry. This “cleat” geometry suppresses slip without 
application of significant normal force, it imposes well-defined shear to enable absolute 
measurements, and is compatible with small sample volumes. The geometry was validated 
in steady and oscillatory shear using a series of materials not prone to slip (Newtonian oils 
and an entangled polymer melt). The advantage of cleated tools over other slip-prevention 
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methods was demonstrated using slip-prone materials, including an emulsion, a 
suspension, and porcine vitreous humor. 
The vitreous humor is a transparent gel comprised of a delicate, swollen double network of 
10 – 20 nm collagen type II fibrils and charged GAG chains (hyaluronic acid). While 
extensive progress has been made in identifying the components and biochemistry of the 
vitreous, prior to the “cleat geometry” experimental limitations hampered quantitative 
determination of its mechanical properties. With cleated tools we overcame wall slip and 
avoided tissue compression during measurements of the dynamic moduli of fresh porcine 
and bovine vitreous. Shear moduli decreased five-fold from initial to steady-state values in 
the first hour after dissection. Steady-state values (Porcine: G′ = 2.6 ± 0.9 Pa and G″ = 0.6 
± 0.4 Pa, n = 9; Bovine: G′ = 6.5 ± 2.0 Pa and G″ = 2.0 ± 0.6 Pa, n = 17) are significantly 
greater than previously reported. The decrease in modulus after removal from the eye 
correlates with a decrease in mass: porcine vitreous expels ~5% of its mass within 5 
minutes and continues to decay to a steady-state mass ~10% lower than its initial mass in 
the absence of external driving forces. The expelled fluid has a substantial hyaluronan 
concentration but a very low protein content. These results indicate that the vitreous 
network is under tension at its native volume, and its high initial modulus results from this 
state of tension. We hypothesize that hyaluronan plays a role in sustaining the “internal 
tension” by Donnan swelling. 
The therapeutic goal in vitreous engineering is liquefaction: we seek pharmacological 
agents capable of gently separating the vitreous from the retina and destabilizing the 
network without damaging the adjacent tissues (retina and lens). We measured the stability 
of the vitreous against agents designed to target covalent bonds, hydrogen bonds, 
electrostatic attractions, and hydrophobic interactions using a simple weighing procedure. 
We found that in addition to covalent bonds, hydrogen bonds appear to play a particularly 
important role in stabilizing the vitreous network. This is in agreement with clinical 
observations that treating eyes with urea prior to vitrectomy provided a significant 
therapeutic benefit. We found that treating porcine vitreous with therapeutic doses of urea 
in vitro reduced the shear modulus by ~ 30%. Limited in vivo animal studies measured no 
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softening effect and indicated that the therapeutic benefit of urea may be a reduction of 
vitreoretinal adhesion. 
The cornea is also composed of collagen fibrils embedded in a PG/GAG matrix. The 
cornea, however, contains far more collagen, PG, and GAG than vitreous, and its 
components are also more ordered: the collagen (type I) is in the form of 30 nm fibrils, 
precisely arranged lamellae and evenly spaced in a keratin sulfate-rich matrix. Our 
therapeutic goal in the cornea is to stabilize its nanostructure and mechanical properties 
against keratoconus, a degenerative disease in which the cornea softens and bows outward 
under the force of intraocular pressure.  
We present coordinated biomechanical and biochemical analyses of corneal tissue that has 
been crosslinked using glycation. Non-enzymatic crosslinking alters the viscoelastic 
properties of protein-rich tissues, but a quantitative correlation between the formation of 
specific advanced glycation end products (AGEs) and physiologically relevant mechanical 
property changes has not previously been established. We report that corneas treated with 
1% and 2% glyceraldehyde solutions produce a 300% and 600% rise in shear modulus, 
respectively, which strongly and linearly correlates with increased fluorescence and the 
formation of the AGEs argpyrimidine, lys-hydroxy-triosidine, and arg-hydroxy-triosidine 
(R2= 0.999, 0.970, and 0.890 respectively). NMR studies are used to demonstrate that 
enzymatic digestion does not alter AGEs and has some advantages over acid hydrolysis. 
The level of mechanical reinforcement observed in these studies is probably sufficient to 
stabilize keratoconus corneas, based upon successful treatments with other crosslinking 
strategies.  
Comparing quantitative correlations between modulus and AGE accumulation in corneas 
with analyses of collagen fibers isolated from mouse tail tendons suggests that glycation-
induced corneal stiffening cannot be attributed solely to changes in collagen. We present a 
novel hypothesis that the mechanically-relevant AGE crosslinks are those that change the 
properties of the soft PG/GAG matrix and its coupling to the collagen fibrils, rather than 
the much more numerous AGEs that crosslink amino acids within fibrils. 
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1.1 Background 
The ability to create and maintain fixed spatial relationships between cells and organs is 
vitally important for higher organisms. Residing in fixed locations allows cells and tissues 
to work cooperatively through specialization and division of labor.1 One illustration of the 
importance of precise physical properties and arrangements is mammalian vision, which 
relies on the precise geometry of the cornea, the mechanical strength of the sclera to 
support the retina, and the orbital ligaments to control the line of sight. 
The mechanical properties of structural tissues such as these are derived from the nanoscale 
architecture and properties of their constituent molecules. Most structural tissues are 
biocomposites of fibrous proteins embedded in soft carbohydrate matrices. Collagen is the 
primary fibrous component; proteoglycans and glycosaminoglycans act as the matrix. The 
hydration state, mole fraction, and organization of these components vary between tissues 
and species, but the basic structure—high tensile-strength fibrils organized in soft 
matrices—is highly preserved. Rare genetic mutations that weaken collagen fibrils or 
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disrupt other aspects of this molecular pattern lead to devastating systemic diseases.2-6 A 
number of more common diseases, such as arthritis and diabetes, are also associated with 
degeneration of collagenous tissues.  
The debilitating nature and prevalence of heritable and degenerative disorders that affect 
connective-tissues has stimulated considerable biochemical and biomechanical research. 
Unfortunately, the molecular (biochemical) and biomechanical aspects of this important 
field have been investigated independently rather than in concert. We will present 
significant advancements that have come as a result of combining biochemical analyses 
with novel bulk characterization techniques. 
Broadly stated, the goal of the present research is to discover and manipulate the molecular 
mechanisms that determine the bulk physical properties of the cornea and vitreous humor 
(Figure 1). This goal can be divided into three specific objectives: 
1) To quantitatively determine the mechanical properties of connective tissues 
2) To understand the molecular basis of these mechanical properties and their 
implications for disease and tissue engineering  
3) To create therapeutic changes in the mechanical properties of the cornea and 
vitreous 
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Figure 1. Diagram of the eye illustrating normal eye anatomy, 
including the vitreous humor (gel) and cornea. This figure 
reproduced by permission from the National Eye Institute, National 
Institutes of Health. 
Our approach to these objectives is to combine analytical chemistry, rheology, and polymer 
physics with in vivo animal studies and the clinical experience of collaborators from 
industry and medicine. Biochemical and biomechanical investigations were conducted in 
parallel with drug discovery and clinical research, providing feedback between clinical and 
laboratory work. Clinical research identified potential therapeutics and evaluations of 
efficacy, while laboratory research addressed fundamental questions regarding the basis of 
the mechanical properties of collagenous tissues and how they can be engineered. The 
success of this approach in exploring potential therapeutics for the vitreous humor and 
cornea demonstrates the utility of an integrated approach to understanding and engineering 
connective tissues in general.  
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1.2 The Vitreous Humor 
The vitreous is a transparent, collagenous gel that fills the posterior chamber of the eye. It 
is more than 98% water, avascular, and nearly acellular; thus, the vitreous was historically 
considered an inert space-filler.7 However, over the past few decades it has become clear 
that the vitreous plays an essential structural role in the development, maintenance, and 
pathologies of vision. Sebag has summarized the functions of the vitreous as 
developmental—mediating proper growth of the eye; optical—maintaining a clear path to 
the retina; mechanical—supporting the various ocular tissues during physical activity; and 
metabolic—providing a repository of various small molecules for the retina.8 Proper 
performance of these functions depends upon the unique physical properties of the vitreous. 
The vitreous is thought to derive its physical properties from its hydrated double network of 
collagen type II fibrils and high molecular-weight, polyanionic hyaluronan macromolecules 
(Figure 2).8-10 Heterotypic collagen fibrils (10 – 20 nm diameter) are composed of a small, 
collagen type V/XI core surrounded by collagen type II. Human vitreous hyaluronan (HA) 
is polydisperse with an average molecular weight that is estimated to be ~ 5,000,000.9 Prior 
literature indicates that the vitreous completely liquefies when digested with collagenase 
enzyme, whereas it only shrinks when digested with hyaluronidase.8, 9, 11 On this basis it 
has been presumed that the network of collagen fibrils provides mechanical strength, and 
the swollen HA macromolecules simply fill the space between fibrils to prevent 
aggregation. In Chapter 3 we will discuss the collagen-HA double network in greater depth 
and present rheological and biochemical evidence that hyaluronan does contribute 
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profoundly to the elastic character of the vitreous. This realization changes the way we 
view the network, particularly in the context of vitreous degeneration and engineering. 
~ 100 nm
Collagen 
type II fibrils
Hyaluronic 
Acid
 
Figure 2. Schematic depiction of the network structure of the 
vitreous. The vitreous is composed of a highly-swollen double 
network of collagen type II fibrils (~ 15 nm in diameter) and 
hyaluronic acid (~ 5M MW). 
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With age the collagen-HA network degrades and loses mechanical integrity: pockets of 
fluid (lacunae) form near the retina as the components of the vitreous network aggregate 
and pull away from the retina.8 Posterior vitreous detachment (PVD) is normally 
inhomogeneous, leaving points of adhesion that cause localized traction on the retina. 
Incomplete PVD and the resultant vitreoretinal traction are thought to play a role in a 
number of diseases, including macular holes, macular edema, vitreous hemorrhage, retinal 
tears, and retinal detachment.8 The only treatment currently available for alleviating 
vitreoretinal traction is surgical removal of the vitreous (vitrectomy).12 Motivated by the 
need for a less invasive and traumatic treatment, efforts have been made to find 
“pharmacological vitrectomy agents” capable of inducing PVD and liquefying or 
significantly softening the vitreous, thereby alleviating traction without surgery.13 Proposed 
therapeutics from the literature will be discussed in detail in Chapter 4, but they generally 
consist of enzymes designed to cleave the proteins responsible for the mechanical integrity 
of the vitreous. Little attention has been given to the possibility of targeting noncovalent 
intermolecular interactions. We present results that indicate that disruption of hydrogen 
bonds strongly destabilizes the vitreous network, whereas disruption of electrostatic or 
hydrophobic interactions has a much weaker effect.  
In addition to collagen type II and HA, 15 “minor” proteins and proteoglycans have been 
identified in the vitreous (Table 1). These components are minor in terms of mass, but may 
be crucial for the structure and stability of the vitreous, much as nails are a “minor” 
component of a wood-framed house. A number of these components, including link 
protein, fibronectin, and vitronectin, are known to connect proteins with polysaccharides in 
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other tissues. They may perform a similar function in the vitreous, stabilizing the 
collagen-HA network and linking it to other structures in the eye; however, little is known 
about the role of minor components in the molecular architecture of the vitreous network. 
Given the importance of the viscoelastic properties of the vitreous to its function and to 
pathology, it is striking that there is no consensus on the value of its modulus in the prior 
literature. This is due in part to a lack of sufficient experimental methods for quantitatively 
measuring the mechanical properties of the vitreous and how they change as a result of 
various treatments.14 To address this need we developed a novel rheological tool that 
enabled us to make the first quantitative measurements of the mechanical properties of the 
vitreous. We discovered that the modulus of the vitreous is significantly higher in situ than 
after removal from the eye. Further exploration of this discovery led us to a novel 
hypothesis regarding the mechanical properties of the vitreous: that HA increases the 
modulus of the vitreous by swelling the collagen network to a state of tension. 
The novel tool also allowed us to measure modulus changes that resulted from treating the 
vitreous with a particular proposed pharmacological vitrectomy agent—urea. Clinical 
observations that urea may facilitate vitreous removal15, 16 led us to investigate its influence 
on the mechanical properties of the vitreous in vitro and in vivo. Slit lamp observations of 
urea-treated vitreous, together with reduced surgical time during vitrectomy, suggested to 
the clinicians that urea “liquefied” the vitreous. By quantitatively characterizing the 
modulus of the vitreous, our work showed that treatment did not liquefy vitreous in vitro or 
in vivo. By working side-by-side with a team of eye surgeons working under the direction 
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of Professor Hugo Quiroz-Mercado at the Hospital “Dr. Luis Sánchez Bulnes” de la 
APEC in Mexico, we were able to reconcile clinical observations with rheological 
measurements. The clinical benefit was more likely the result of reduced vitreoretinal 
adhesion and phase separation as the collagen network contracted away from the retina to 
relieve tension. We also explored the effects of other agents on vitreous and found that 
hydrogen bonding plays a more significant role in stabilizing the vitreous network than 
electrostatic or hydrophobic effects. Taken together, these results provide a basis for 
rational design of future pharmacological vitrectomy agents. 
 
Component Concentration   
Human/Pig 
[μg/ml] 
Location Proposed functions
Water >980,000
9/ 
same Throughout 
Maintains vitreous mechanical 
properties and facilitates 
transport7 
Salts (NaCl, 
KCl, CaCl2, and 
MgCl2) 
~9,0009/same Throughout 
Global charge balance, Donnan 
swelling; vitreous is isotonic 
with blood and most other 
tissues7 
Total Protein 8007/70017 Throughout — 
Total 
polysaccharide 240
18/~25017 Throughout — 
Collagen type II ~2259/15017 
Throughout as 
heterotypic 
fibrils 
Resist elongation of the eye and 
provide structural framework for 
the vitreous body7 
Hyaluronic acid 65-4009/16517 Throughout 
Resist compression of the eye, 
hydrate tissue, space collagen 
fibrils7 
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Albumin 29319/ Throughout Soluble protein, no known structural role 
Link protein 0.6(bovine)20 Unknown 1:1 with versican; it may be there to link versican to HA20 
Collagen V/XI ~30
9/ 
Unknown Throughout 
Form the core of heterotypic 
collagen II fibrils9 
Collagen IX <309/ Unknown Throughout 
Decorate surface of heterotypic 
collagen II fibrils, prevent fibril 
aggregation, possibly link fibrils 
to noncollagenous components9 
Collagen VI21 Unknown 
Concentrated 
on the zonular 
fibers 
Bind collagen fibrils to HA and 
other species (has been shown to 
bind von Willebrand factor, 
collagen II fibrils, decorin and 
HA)22, 23 
Collagen XVIII9 Unknown Vitreoretinal interface 
Vitreoretinal adhesion; has been 
co-localized  with opticin at 
vitreoretinal interface; contains 
endostatin as a non-collagenous 
domain9 
Cartilage 
oligomeric 
matrix protein 
(COMP)24 
Unknown Unknown 
Unknown, but also found in 
cartilage and tendon; contains 
von Willebrand factor domains 
(see collagen VI)25 
Microfibril-
associated 
glycoprotein-1 
(MAGP1)26 
Unknown Unknown Decorate exterior of zonular fibers26 
Opticin9 Unknown 
Vitreous  base 
and lamina 
cribrosa 
Acts in conjunction with 
collagen XVIII to mediate 
vitreoretinal adhesion9 
Fibrillin 
Minor but 
probably > 
[coll VI]9 
Attached to 
lens capsule 
Structural fibrils for lens capsule 
anchoring & articulation9 
Fibronectin 6
9/ 
>76(bovine)27 Throughout 
Mediate binding between 
collagen and polysaccharides25 
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Vitronectin 428/ Unknown Unknown 
Mediate collagen-polysaccharide 
binding; sensitive to 
denaturation25 
Versican 60
29/ 
22(bovine)20 Unknown 
1 per 150 moles of HA; possible 
link between HA and collagen 
and has been show to dissociate 
(if it was associated) in 4M 
guanidinium HCL; HA binding 
has been demonstrated17, 25 
VIT130 Unknown Unknown May have structural role30 
Laminin/ 
Collagen type 
IV31 
Unknown 
Inner limiting 
membrane 
surrounding 
vitreous 
While not components of the 
vitreous proper, they may 
participate in peripheral vitreous 
adhesion 
Table 1. Known components of the vitreous humor listed with available 
information regarding concentration (μg / mL), distribution, and proposed function. 
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1.3 The Cornea 
Like the vitreous, the cornea is composed of collagen fibrils embedded in a proteoglycan 
(PG) and glycosaminoglycan (GAG) matrix; however, unlike the vitreous, the cornea has a 
highly-ordered structure. The major structural element of the cornea (~ 90% of its 
thickness) is the stroma, which is composed of approximately 200 lamellae of oriented 
collagen type I fibrils embedded in a hydrated PG/GAG12 (Figure 3). The precise 
arrangement of collagen fibrils allows the cornea to retain optical clarity in spite of the 
relatively high density of collagen fibrils (30 nm diameter) required to retain the shape of 
the cornea.  
C
A
~ 20 nm
~ 2 nm
~ 6 μm
lamella
triple helix
fibril
B
 
Figure 3. Stroma microstructure. [A] Represents the rigid collagen 
type I fibrils and smaller strands of proteoglycan that compose the 
lamellae of the corneal stroma. [B] Shows an enlargement of part of 
one of the fibrils, displaying the collagen triple helices aligned within 
a fibril. [C] Depicts the protein core of a proteoglycan non-
covalently associated with the surface of a collagen fibril and 
decorated with polysaccharide chains. Micrograph was used by 
permission from Prof. K. Kadler, U. Manchester. 
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Whereas a primary therapeutic objective in the vitreous is softening and inducing PVD to 
alleviate vitreoretinal traction, a major, unmet clinical need in the cornea is enhancing its 
mechanical stability to prevent the progression of keratoconus. Keratoconus (“cone-shaped 
cornea”) is a condition in which the cornea softens and slowly begins to protrude outward 
under the force of intraocular pressure.12 It affects roughly 1 in 2,000 people, normally 
beginning in the teens or early twenties, and causes progressive loss of visual acuity, 
eventually leading to blindness.32 In early stages, keratoconus is treated by application of 
hard contact lenses that correct vision and help maintain the shape of the cornea. If 
keratoconus progresses further, cornea transplantation is the only known treatment. The 
expense and difficulty of obtaining transplant tissue and the invasive nature of the surgery 
motivate our efforts to find a chemical treatment for keratoconus. 
Collaborators at ISTA Pharmaceuticals, Inc. (Irvine, CA) developed a non-toxic, glycation-
based crosslinking strategy to stabilize the cornea against keratoconus using glyceraldehyde 
(GA). Glyceraldehyde reacts with primary amines to form several known advanced 
glycation endproducts (AGEs), including two crosslinks and three AGEs that are also 
formed in reactions with methylglyoxal (MGO), another species investigated in this work 
(Figure 4). We have demonstrated that therapeutic (nontoxic) doses of glyceraldehyde are 
capable of significantly increasing the shear modulus of porcine corneas. Equivalent 
increases in modulus, achieved through alternative crosslinking strategies, have been 
shown to stabilize keratoconus eyes in clinical trials.33, 34 
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Figure 4. Glyceraldehyde, glyceraldehyde-3-phosphate (GA-3-
phosphate), and methylglyoxal (MGO) all lead to similar AGEs, 
including argpyrimidine, arg-OH-triosidine, lys-OH-triosidine, and 
carboxyethyl lysine. RNH2 indicates a primary amine on the side 
chain of an Arg or Lys residue within a peptide. 
Biochemical analyses of GA-treated corneas revealed an additional protective effect of GA 
treatment: they are far less susceptible to proteolytic degradation (Chapter 5). This is 
particularly significant in light of the current hypothesis that keratoconus-induced softening 
comes as a result of overactive proteases in the cornea.35 The enzyme protective effect also 
indicates that GA may be a suitable treatment for corneal ulcers, which have also been 
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linked to increased proteolytic activity and treated with crosslinking strategies.36 The 
effect of GA on corneal ulcers has not yet been addressed. 
Glycation-induced changes in enzyme resistance and modulus also correlate with increased 
fluorescence and AGE accumulation. We were able to isolate and quantify specific AGEs 
from glycated corneas and demonstrate that modulus increases linearly with accumulation 
of each of them, including argpyrimidine, a pendent adduct. Thus, it appears that 
crosslinking and noncrosslinking AGEs rise together and that various individual AGEs 
could serve as a surrogate to track tissue stiffening, whether or not the individual surrogate 
AGE is a crosslink. It may be possible to use an equivalent empirical relation to 
noninvasively measure (e.g., by fluorescence) the degree of tissue stiffening in clinical 
practice. 
Quantitative correlations between the chemical and mechanical impact of glycation on 
corneal tissue also yield new insight into the molecular mechanisms of AGE-related tissue 
stiffening. The literature holds that glycation stiffens collagenous tissues by changing the 
properties of the constituent collagen fibrils;37, 38 however, our results demonstrate that 
glycation-induced corneal stiffening cannot be attributed solely to changes in the properties 
of the collagen fibrils. We present a novel hypothesis that the mechanically relevant AGE 
crosslinks are those that change the properties of the soft PG/GAG matrix and its coupling 
to the collagen fibrils, rather than the much more numerous AGEs that crosslink amino 
acids within fibrils. 
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New insights into the increase in modulus associated with AGEs may also be broadly 
relevant to aging, diabetes, and tissue engineering research. The mechanisms by which 
glycation stiffens tissues in vitro may be relevant to certain pathologies of aging and 
diabetes. When properly understood, glycation has the potential to be turned from a 
pathologic process to a therapeutic strategy. The cornea is a good example, but it is merely 
a case-in-point. This strategy can be applied to a number of areas, from wound healing to 
bioadhesion to improving the mechanical properties of protein-based and polyamide 
synthetic tissues. Imparting strength to weakened connective tissue through glycation may 
provide an alternative to tissue transplants in diseases such as keratoconus. 
1.4 Broader Implications 
A unifying theme that emerges from both the vitreous and cornea work is that collagenous 
tissues depend integrally on the contributions of their carbohydrate components for 
mechanical strength. We hope that future efforts to engineer the mechanical properties of 
collagenous tissues will recognize the important mechanical role of carbohydrate 
components and apply this knowledge in the design of therapeutics. 
The overarching goal of this thesis is to bridge the gap between the chemical, 
biomechanical, and clinical aspects of tissue engineering. Working closely with physicians 
to focus on these three aspects in parallel has allowed developments from the lab to rapidly 
influence therapeutic formulations for clinical trial (e.g., optimal pH of urea treatment), and 
feedback on the in vivo relevance of in vitro discoveries allowed us to rapidly verify the 
significance of new findings. We hope that the success we have had in elucidating the 
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molecular interactions that play a significant role in biomechanics will provide a model 
for productive cross-field collaborations.  
1.5 Organization of Thesis 
There were no rheological methods suitable for quantitative characterization of the vitreous 
prior to this work. Chapter 2 presents the novel “cleat geometry” developed specifically for 
this purpose. 
Chapters 3 and 4 address the properties and network structure of the vitreous. In Chapter 3 
the mechanical properties of the vitreous are defined. A novel hypothesis regarding a direct 
contribution of hyaluronic acid to the mechanical stiffness of the vitreous is also presented. 
In Chapter 4 the stability of the vitreous network in various chemical environments is 
examined as a basis for selecting potential pharmacological vitrectomy agents. Hydrogen 
bonding is shown to play a key role in stabilizing the vitreous network and urea is 
examined as a potential therapeutic for softening the vitreous. 
Chapters 5 and 6 address glycation in the cornea. In Chapter 5 the chemical and mechanical 
impact of glycating corneal tissue with glyceraldehyde is examined. In Chapter 6 
mechanical measurements of glycated collagen fibers from mouse tail tendons are used to 
demonstrate that the enhanced mechanical strength of glycated collagenous tissues cannot 
be attributed solely to the stiffening of collagen fibrils – the surrounding matrix 
(presumably proteoglycans) must also play a role. 
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